Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

Inclusion Criteria:

Clinical diagnosis of stable plaque-type psoriasis affecting 2% to 10% of the subject's body surface area
Psoriasis of a severity that is appropriate for treatment with topical therapy; PGA of at least 3 (moderate) at baseline; PSS of at least 7, and with no individual symptom score (erythema, induration, or scaling) less than 2
Subject must sign the IRB approved informed consent and agree to follow dosing instructions and complete required clinic visits.

Exclusion Criteria:

Pregnant or nursing females
Systemic corticosteroids, methotrexate, cyclosporine, systemic retinoids, prolonged sun exposure or ultraviolet light therapy within 4 weeks of dosing
Topical corticosteroids, retinoids, calcipotriene, coal tar, anthralin, or any other treatment indicated for psoriasis within 2 weeks of dosing
Untreated bacterial, tubercular, fungal or any viral lesion of the skin
Biologic agents/monoclonal antibodies in the last 6 months
Currently using lithium or plaquenil
Currently using a beta-blocking medication or thiazide diuretic and the dose has not been stabilized for at least 6 months
History of hypercalcemia or evidence of vitamin D toxicity
Current or history of melanoma skin cancer in the past 5 years